Delpacibart etedesiran is under clinical development by Avidity Biosciences and currently in Phase III for Myotonic Dystrophy. According to GlobalData, Phase III drugs for Myotonic Dystrophy does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Delpacibart etedesiran LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Delpacibart etedesiran overview
Avidity Biosciences overview
Avidity Biosciences is a biotechnology company that focuses on the development of RNA therapeutics. The company’s primary activities focuses on the creation and advancement of its proprietary antibody oligonucleotide conjugates (AOC) platform, that combines the specificity of monoclonal antibodies with the precision of oligonucleotides. Avidity Biosciences’ major products include AOC programs for rare diseases such as myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and duchenne muscular dystrophy (DMD). Its products are primarily used in the healthcare industry, specifically in the treatment of muscle diseases. The company operates in the US. Avidity Biosciences is headquartered in San Diego, California, the US.
For a complete picture of Delpacibart etedesiran’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
